Based on these data, the FDA approved tesamorelin (marketed as EGRIFTA) for the reduction of excess abdominal fat in HIVassociated lipodystrophy, not as a general weightloss drug for the wider population. Tesamorelin Risks and Considerations Like all hormonemodulating therapies, tesamorelin carries potential risks, including fluid retention, joint pain, injectionsite reactions, and effects on glucose metabolism in susceptible patients
Reporting of side effects: If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect not listed in this leaflet
Yet, only a few are proven effective
The rationale for stacking a GHRH analog with a ghrelin-receptor agonist is a theorized synergy : sustained GH elevation (from CJC-1295) plus consistent GH peaks (from Ipamorelin)
Was it mindset
Why should I purchase a subscription